Australian PM Morrison: Have no advice to change to AstraZeneca covid vaccine rollout
|Australian Prime Minister Morrison said that he has no advice at present to change the AstraZeneca covid vaccine rollout.
This comes amid conflicting reports from the UK and Europe Health regulators.
On Wednesday, the European Medicines Agency (EMU) said that unusual blood clots should be listed as a very rare side effect of the AstraZeneca vaccine for Covid-19.
After a study looking at 86 European cases, the EMA concluded the benefits of the vaccine outweighed the risk.
Separately, the UK’s Medicines and Healthcare products Regulatory Agency considered outlining a proposal, which would restrict the use of the Oxford-AstraZeneca covid vaccine in younger people over concerns about very rare blood clots.
Meanwhile, the World Health Organization's (WHO) advisory vaccine safety panel said on Wednesday that although a blood clot link was "plausible" it was "not confirmed" and the cases were "very rare" among 200 million people vaccinated with AstraZeneca globally.
Market implications
The mixed vaccine reviews are boding ill for the Asian equities while the US dollar clings onto the overnight gains.
AUD/USD is attempting a rebound from 0.7600, now trading flat at 0.7614, lacking a follow-through bias.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.